Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

被引：0
|
作者：
Dabkara, Deepak [1 ]
Bajpai, Jyoti [1 ]
机构：
[1] All India Inst Med Sci, Inst Rotary Canc Hosp, Dept Med Oncol, New Delhi 110029, India
来源：
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY | 2008年 / 29卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：10 / 13
页数：4
相关论文
共 50 条
  • [41] Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Wakabayashi, Masashi
    Tsukasaki, Kunihiro
    Miyamoto, Kenichi
    Maruyama, Dai
    Yamamoto, Kazuhito
    Takatsuka, Yoshifusa
    Kusumoto, Shigeru
    Kuroda, Junya
    Ando, Kiyoshi
    Kikukawa, Yoshitaka
    Masaki, Yasufumi
    Kobayashi, Miki
    Hanamura, Ichiro
    Asai, Hiroaki
    Nagai, Hirokazu
    Shimada, Kazuyuki
    Tsukamoto, Norifumi
    Inoue, Yoshiko
    Tobinai, Kensei
    [J]. CANCER SCIENCE, 2018, 109 (05) : 1552 - 1561
  • [42] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    [J]. BLOOD, 2017, 130 (08) : 974 - 981
  • [43] Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Stadtmauer, Edward A.
    Rajkumar, S. Vincent
    Siegel, David
    Bravo, Marie-Laure
    Olesnyckyj, Marta
    Knight, Robert D.
    Zeldis, Jerome B.
    Harousseau, Jean-Luc
    Weber, Donna M.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 38 - 43
  • [44] Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma
    Siegel, David Samuel DiCapua
    McBride, Laura
    Bilotti, Elizabeth
    Schmidt, Linda
    Gao, Zhijie
    Tufail, Madiha
    Lendvai, Nikoletta
    McNeill, Ann
    Donadio, Kristen
    Olivo, Karly
    Bednarz, Urzula
    Graef, Thorsten
    Vesole, David H.
    [J]. BLOOD, 2010, 116 (21) : 1264 - 1264
  • [45] Lenalidomide plus dexamethasone in multiple myeloma
    Das, Manjulika
    [J]. LANCET ONCOLOGY, 2018, 19 (01): : E12 - E12
  • [46] Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma
    Minarik, Jiri
    Pika, Tomas
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Mistrik, Martin
    Brozova, Lucie
    Krhovska, Petra
    Machalkova, Katerina
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Capkova, Lenka
    Sykora, Michal
    Kessler, Petr
    Stejskal, Lukas
    Heindorfer, Adriana
    Ullrychova, Jana
    Maisnar, Vladimir
    Hajek, Roman
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E271 - E272
  • [47] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
    Paludo, Jonas
    Mikhael, Joseph R.
    LaPlant, Betsy R.
    Halvorson, Alese E.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    Stewart, A. Keith
    Reeder, Craig B.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    [J]. BLOOD, 2017, 130 (10) : 1198 - 1204
  • [48] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    David S. Siegel
    Gary J. Schiller
    Christy Samaras
    Michael Sebag
    Jesus Berdeja
    Siddhartha Ganguly
    Jeffrey Matous
    Kevin Song
    Christopher S. Seet
    Giampaolo Talamo
    Mirelis Acosta-Rivera
    Michael Bar
    Donald Quick
    Bertrand Anz
    Gustavo Fonseca
    Donna Reece
    William E. Pierceall
    Weiyuan Chung
    Faiza Zafar
    Amit Agarwal
    Nizar J. Bahlis
    [J]. Leukemia, 2020, 34 : 3286 - 3297
  • [49] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy
    Sebag, Michael
    Berdeja, Jesus
    Ganguly, Siddhartha
    Matous, Jeffrey
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Pierceall, William E.
    Chung, Weiyuan
    Zafar, Faiza
    Agarwal, Amit
    Bahlis, Nizar J.
    [J]. LEUKEMIA, 2020, 34 (12) : 3286 - 3297
  • [50] LONG TERM TREATMENT WITH LENALIDOMIDE-DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Rocchi, S.
    Petrucci, M. T.
    Zambello, R.
    Montefusco, V.
    Pantani, L.
    Gamberi, B.
    Rizzello, I.
    Nozzoli, C.
    Dozza, L.
    Borsi, E.
    De Paoli, L.
    Palmieri, S.
    Cellini, C.
    di Toritto, T. Caravita
    Tosi, P.
    Morabito, F.
    Gozzetti, A.
    Cavo, M.
    [J]. HAEMATOLOGICA, 2017, 102 : 129 - 130
12345